PHAS Insider Trading (PhaseBio Pharmaceuticals)

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 17.00%

Insider Buying (Last 12 Months): $42,720.00

Insider Selling (Last 12 Months): $12,064.65

PhaseBio Pharmaceuticals Insider Trading History Chart

PhaseBio Pharmaceuticals Share Price & Price History

^$3.88

▼ -0.01 (-0.26%)

As of 02/26/2021 01:00 AM ET

Days: 30 | 90 | 365

Man Gets Into a Tesla… What Happens Next Will Shock Everyone (Video)

From Legacy Research | Ad

"Hi, I'm Jeff Brown… I'm about to get in this Tesla and drive up to a location just a few miles from here to show you Elon Musk's next big project…

What happens next will shock you…"

Click here to see what happened.

PhaseBio Pharmaceuticals Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/3/2020	Edmund Harrigan	Director	Buy	6,000	$4.12	$24,720.00	6,000
11/24/2020	Clay Thorp	Director	Buy	5,000	$3.60	$18,000.00
11/23/2020	Glen Burkhardt	VP	Sell	3,497	$3.45	$12,064.65	3,497
7/1/2019	Clay Thorp	Director	Sell	2,908	$14.00	$40,712.00
6/18/2019	Clay Thorp	Director	Sell	400	$14.00	$5,600.00
12/17/2018	Nancy J Hutson	Director	Buy	1,000	$4.46	$4,460.00
12/13/2018	Jonathan P Mow	CEO	Buy	1,000	$3.69	$3,690.00
12/11/2018	Michael York	VP	Buy	1,500	$3.88	$5,820.00
12/10/2018	Jonathan P Mow	CEO	Buy	3,000	$3.87	$11,610.00
12/7/2018	John P Sharp	CFO	Buy	5,000	$3.84	$19,200.00
12/4/2018	Clay Thorp	Director	Buy	4,000	$3.13	$12,520.00
10/22/2018	Linda Tufts	Director	Buy	20,000	$5.00	$100,000.00
10/22/2018	Venture Advisors Iii Hatteras	Major Shareholder	Buy	300,000	$5.00	$1,500,000.00

SEC Filings (Institutional Ownership Changes) for PhaseBio Pharmaceuticals (NASDAQ:PHAS)

58.58% of PhaseBio Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

PhaseBio Pharmaceuticals Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
2/24/2021	Virtu Financial LLC	28,821	$97K	0.0%	N/A	0.098%
2/19/2021	JPMorgan Chase & Co.	41,006	$0.14M	0.0%	+616.6%	0.140%
2/16/2021	ETF Managers Group LLC	14,283	$50K	0.0%	-13.1%	0.049%
2/12/2021	Stifel Financial Corp	210,125	$0.71M	0.0%	+11.9%	0.716%
2/10/2021	Rhumbline Advisers	10,492	$35K	0.0%	N/A	0.036%
2/10/2021	Renaissance Technologies LLC	83,400	$0.28M	0.0%	N/A	0.284%
2/9/2021	Wells Fargo & Company MN	24,792	$83K	0.0%	+17.8%	0.084%
2/9/2021	Bank of New York Mellon Corp	36,965	$0.13M	0.0%	-7.0%	0.126%
2/9/2021	Blair William & Co. IL	67,500	$0.23M	0.0%	N/A	0.230%
2/5/2021	BlackRock Inc.	1,193,607	$4.01M	0.0%	+5.2%	4.065%
2/4/2021	GSA Capital Partners LLP	140,341	$0.47M	0.1%	-9.1%	0.478%
11/30/2020	Platform Technology Partners	92,950	$0.33M	0.2%	+72.2%	0.317%
11/13/2020	Morgan Stanley	101,650	$0.36M	0.0%	-37.1%	0.346%
11/10/2020	State Street Corp	300,757	$1.06M	0.0%	+16.5%	1.025%
11/6/2020	BlackRock Inc.	1,134,939	$3.98M	0.0%	+4.9%	3.868%
11/6/2020	GSA Capital Partners LLP	154,316	$0.54M	0.1%	N/A	0.526%
8/31/2020	Bridgeway Capital Management Inc.	152,600	$0.70M	0.0%	-16.8%	0.520%
8/25/2020	Nuveen Asset Management LLC	32,355	$0.15M	0.0%	-23.9%	0.110%
8/20/2020	Charles Schwab Investment Management Inc.	40,648	$0.19M	0.0%	+10.5%	0.139%
8/14/2020	Bank of America Corp DE	7,171	$33K	0.0%	+73.5%	0.025%
8/14/2020	Sabby Management LLC	76,970	$0.35M	0.1%	-28.5%	0.267%
8/12/2020	Goldman Sachs Group Inc.	28,517	$0.13M	0.0%	-41.0%	0.099%
8/3/2020	Leap Investments LP	15,800	$73K	0.0%	N/A	0.055%
7/22/2020	First Trust Advisors LP	30,008	$0.14M	0.0%	+7.7%	0.104%
7/16/2020	Wedbush Securities Inc.	11,400	$52K	0.0%	N/A	0.040%
6/19/2020	State Street Corp	249,310	$0.83M	0.0%	+8.5%	0.866%
5/15/2020	Sabby Management LLC	107,577	$0.36M	0.1%	+14.0%	0.374%
5/15/2020	Morgan Stanley	85,623	$0.28M	0.0%	-16.5%	0.297%
5/15/2020	DAFNA Capital Management LLC	320,542	$1.06M	0.4%	-11.1%	1.114%
5/15/2020	Ghost Tree Capital LLC	497,074	$1.65M	0.4%	+10.5%	1.727%
5/14/2020	Wells Fargo & Company MN	16,832	$55K	0.0%	+107.0%	0.058%
5/14/2020	Geode Capital Management LLC	214,659	$0.71M	0.0%	+13.1%	0.746%
5/14/2020	Wellington Management Group LLP	4,027,284	$13.33M	0.0%	+3.5%	13.993%
5/14/2020	Nuveen Asset Management LLC	42,501	$0.14M	0.0%	+14.8%	0.148%
5/11/2020	State Street Corp	249,310	$0.83M	0.0%	+8.5%	0.866%
5/6/2020	First Trust Advisors LP	27,875	$92K	0.0%	-16.2%	0.097%
5/6/2020	Bank of New York Mellon Corp	41,251	$0.14M	0.0%	+16.1%	0.143%
5/1/2020	BlackRock Inc.	989,790	$3.28M	0.0%	-1.0%	3.439%
5/1/2020	UBS Group AG	9,863	$33K	0.0%	-45.4%	0.034%
2/20/2020	Geode Capital Management LLC	189,717	$1.16M	0.0%	+4.0%	0.659%
2/14/2020	Goldman Sachs Group Inc.	116,413	$0.71M	0.0%	+6.0%	0.405%
2/14/2020	UBS Group AG	18,059	$0.11M	0.0%	+39.8%	0.063%
2/13/2020	Parkman Healthcare Partners LLC	91,091	$0.56M	0.2%	N/A	0.317%
2/13/2020	Farallon Capital Management LLC	1,000,000	$6.11M	0.0%	+23.8%	3.476%
2/13/2020	Stifel Financial Corp	163,043	$0.98M	0.0%	-19.9%	0.567%
2/12/2020	Sectoral Asset Management Inc	178,000	$1.09M	0.2%	-9.2%	0.619%
2/11/2020	TD Asset Management Inc.	43,843	$0.27M	0.0%	+11.4%	0.152%
2/11/2020	Quantitative Systematic Strategies LLC	10,947	$67K	0.0%	N/A	0.038%
2/10/2020	Barclays PLC	21,969	$0.13M	0.0%	+41.1%	0.076%
2/6/2020	Acadian Asset Management LLC	13,799	$84K	0.0%	+179.4%	0.048%
2/6/2020	State Street Corp	229,779	$1.40M	0.0%	+3.9%	0.799%
2/4/2020	Virtu Financial LLC	13,422	$82K	0.0%	N/A	0.047%
1/10/2020	FNY Investment Advisers LLC	10,000	$61K	0.0%	N/A	0.035%
11/27/2019	Millennium Management LLC	60,146	$0.25M	0.0%	N/A	0.209%
11/27/2019	Sabby Management LLC	124,788	$0.52M	0.3%	+50.5%	0.434%
11/27/2019	Barclays PLC	15,566	$65K	0.0%	-40.7%	0.054%
11/27/2019	Stifel Financial Corp	203,458	$0.84M	0.0%	+178.9%	0.707%
11/27/2019	State Street Corp	221,242	$0.92M	0.0%	+16.6%	0.769%
11/4/2019	Alps Advisors Inc.	55,856	$0.23M	0.0%	-5.0%	0.195%
11/4/2019	First Trust Advisors LP	33,855	$0.14M	0.0%	N/A	0.118%
9/11/2019	River & Mercantile Asset Management LLP	20,000	$0.26M	0.0%	N/A	0.070%
8/16/2019	United Services Automobile Association	107,267	$1.41M	0.0%	+15.8%	0.438%
8/15/2019	River & Mercantile Asset Management LLP	20,000	$0.26M	0.0%	N/A	0.070%
8/15/2019	Price T Rowe Associates Inc. MD	796,236	$10.45M	0.0%	+22.2%	3.250%
8/14/2019	Morgan Stanley	84,194	$1.10M	0.0%	+3,673.8%	0.344%
8/14/2019	Cormorant Asset Management LP	906,229	$11.89M	0.7%	+7.9%	3.699%
8/14/2019	Vanguard Group Inc.	673,620	$8.84M	0.0%	+266.1%	2.750%
8/14/2019	Farallon Capital Management LLC	756,961	$9.93M	0.1%	N/A	3.090%
8/14/2019	Rock Springs Capital Management LP	1,423,256	$18.67M	0.7%	+24.8%	5.810%
8/13/2019	BlackRock Inc.	895,427	$11.75M	0.0%	+1,878.4%	3.655%
8/13/2019	Virtus ETF Advisers LLC	22,949	$0.30M	0.1%	N/A	0.094%
8/13/2019	Northern Trust Corp	37,027	$0.49M	0.0%	N/A	0.151%
8/12/2019	Bank of New York Mellon Corp	38,169	$0.50M	0.0%	N/A	0.156%
8/10/2019	Charles Schwab Investment Management Inc.	36,799	$0.48M	0.0%	N/A	0.150%
8/7/2019	Alps Advisors Inc.	58,775	$0.77M	0.0%	N/A	0.240%
8/7/2019	NEA Management Company LLC	6,643,704	$87.17M	6.1%	N/A	27.117%
8/7/2019	JPMorgan Chase & Co.	3,769	$48K	0.0%	N/A	0.015%
8/6/2019	Wells Fargo & Company MN	16,046	$0.21M	0.0%	N/A	0.065%
8/1/2019	TD Asset Management Inc.	40,343	$0.53M	0.0%	+26.9%	0.165%
6/30/2019	Strs Ohio	3,700	$48K	0.0%	N/A	0.015%
4/4/2019	Tibra Equities Europe Ltd	22,778	$0.22M	0.0%	N/A	0.093%
2/15/2019	Millennium Management LLC	133,022	$0.41M	0.0%	N/A	0.543%
2/13/2019	United Services Automobile Association	92,614	$0.29M	0.0%	N/A	0.378%
2/12/2019	Citigroup Inc.	113,605	$0.35M	0.0%	N/A	0.464%
2/8/2019	BlackRock Inc.	25,309	$79K	0.0%	N/A	0.103%

Data available starting January 2016

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is PB2452, a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients experiencing uncontrolled bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440, an oral agent for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was founded in 2002 and is based in Malvern, Pennsylvania.

Today's Range

Now: $3.88

$3.76

$4.02

50 Day Range

MA: $4.28

$3.74

$5.55

52 Week Range

Now: $3.88

$2.60

$6.85

Volume

167,093 shs

Average Volume

347,815 shs

Market Capitalization

$113.94 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.85

Who are the company insiders with the largest holdings of PhaseBio Pharmaceuticals?

PhaseBio Pharmaceuticals' top insider shareholders include:

Edmund Harrigan (Director)
Glen Burkhardt (VP)
Clay Thorp (Director)

Who are the major institutional investors of PhaseBio Pharmaceuticals?

PhaseBio Pharmaceuticals' top institutional shareholders include:

BlackRock Inc. — 4.06%
Stifel Financial Corp — 0.72%
GSA Capital Partners LLP — 0.48%
Renaissance Technologies LLC — 0.28%
Blair William & Co. IL — 0.23%
JPMorgan Chase & Co. — 0.14%

Which major investors are selling PhaseBio Pharmaceuticals stock?

In the previous quarter, PHAS stock was sold by these institutional investors:

GSA Capital Partners LLP
Bank of New York Mellon Corp
ETF Managers Group LLC

Which major investors are buying PhaseBio Pharmaceuticals stock?

During the last quarter, PHAS stock was purchased by institutional investors including:

Renaissance Technologies LLC
Blair William & Co. IL
BlackRock Inc.
JPMorgan Chase & Co.
Virtu Financial LLC
Stifel Financial Corp
Rhumbline Advisers
Wells Fargo & Company MN

Within the last year, these company insiders have bought PhaseBio Pharmaceuticals stock:

Edmund Harrigan (Director)
Glen Burkhardt (VP)